Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
Titel:
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
Auteur:
Kuruvilla, John Ramchandren, Radhakrishnan Santoro, Armando Paszkiewicz-Kozik, Ewa Gasiorowski, Robin Johnson, Nathalie A Fogliatto, Laura Maria Goncalves, Iara de Oliveira, Jose S R Buccheri, Valeria Perini, Guilherme F Goldschmidt, Neta Kriachok, Iryna Dickinson, Michael Komarnicki, Mieczyslaw McDonald, Andrew Ozcan, Muhit Sekiguchi, Naohiro Zhu, Ying Nahar, Akash Marinello, Patricia Zinzani, Pier Luigi